Monitor for clinical trial initiation in Q4 2026 and initial readout in H1 2027. The filing does not alter the near-term financial outlook; the stock remains a speculative micro-cap with no revenue. Watch for capital needs to fund the upcoming clinical work.
Price Chart
Executive Summary
Glucotrack's subsidiary Lokahi Therapeutics announced progress in its LT-100 development strategy, moving from a 15-injection intradermal regimen toward a single subcutaneous injection. An FDA Type C meeting in May 2026 and a nonclinical minipig study support the planned clinical evaluation, expected to begin as early as Q4 2026 with an initial readout in H1 2027. This is an early-stage pipeline update with no financial data or material near-term impact.
Key Facts
- FDA Type C meeting held in May 2026 to discuss LT-100 clinical strategy
- Nonclinical minipig study completed comparing subcutaneous vs intradermal administration
- Company plans clinical evaluation of single subcutaneous injection as early as Q4 2026
- Initial readout potentially in H1 2027
- LT-100 historically required up to 15 intradermal injections per treatment visit
Financial Impact
No financial figures disclosed; pre-revenue clinical-stage development update
Risk Factors
- Clinical trial enrollment and execution risks
- Regulatory uncertainty (FDA approval not guaranteed)
- Need for additional capital to fund operations and clinical development
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 10 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (GCTK) — Batch item 1 | 0001493152-26-035503 |
| Exhibit: ex99-1.htm | 0001493152-26-035503 |
| Document: 0001493152-26-035503-index-headers.html | 0001493152-26-035503 |
| Document: 0001493152-26-035503-index.html | 0001493152-26-035503 |
| Document: 0001493152-26-035503.txt | 0001493152-26-035503 |
| 8-K Filing (GCTK) — Batch item 6 | 0001493152-26-035503 |
| Exhibit: ex99-1.htm | 0001493152-26-035503 |
| Document: 0001493152-26-035503-index-headers.html | 0001493152-26-035503 |
| Document: 0001493152-26-035503-index.html | 0001493152-26-035503 |
| Document: 0001493152-26-035503.txt | 0001493152-26-035503 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 8-K | $0.4032 | awaiting T+60 | — | — |
Oct 19, 2026 7d ago | 8-K | $0.6511 | awaiting T+60 | — | — |
Oct 13, 2026 12d ago | S-1/A | $0.8873 | awaiting T+60 | — | — |
Oct 13, 2026 13d ago | 425 | $0.8873 | awaiting T+60 | — | — |
Sep 28, 2026 28d ago | 8-K | $1.74 | awaiting T+60 | — | — |
Sep 24, 2026 4w ago | 424B5 | $1.82 | awaiting T+60 | — | — |
Sep 24, 2026 4w ago | 8-K | $1.82 | awaiting T+60 | — | — |
Sep 23, 2026 4w ago | 425 | $2.03 | awaiting T+60 | — | — |
Sep 23, 2026 4w ago | 8-K | $2.03 | awaiting T+60 | — | — |
Sep 18, 2026 5w ago | 8-K | $2.30 | awaiting T+60 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers